Editas Medicine Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 14.97, 14.79, 7.17, 10.68, 8.5 ], "ebit_estimate": [ -108.9, -121.39, -143.31, -152.98, -165.33 ], "ebitda_estimate": [ -106.33, -117.68, -129.19, null, null ], "net_income_estimate": [ -107.55, -120.27, -138.93, -151.73, -163.67 ], "per_share_eps_estimate": [ -1, -0.97, -1.05, -1.02, -1.05 ], "eps_nri_estimate": [ -0.99, -0.97, -1.01, -1.02, -1.05 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -1.22, null, null, null, null ], "pretax_income_estimate": [ -107.39, -121.47, -138.93, -151.73, -163.67 ], "operating_cash_flow_per_share_estimate": [ -0.92, -0.76, -1.55, null, null ], "roa_estimate": [ -53.9, -49.8, null, null, null ], "roe_estimate": [ -123.71, -90.22, -82.99, null, null ], "gross_margin_estimate": [ 85, 40, 50, null, null ], "operating_cash_flow_estimate": [ -89.56, -74.39, -151.71, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 16.11, "long_term_revenue_growth_rate_mean": "-40.60", "future_per_share_eps_estimate_growth": 15.28, "future_eps_nri_estimate_growth": 16.11, "future_revenue_estimate_growth": -40.6, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 25.37, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 2.8, 3.12, 6.28, 2.1, 2.12, 2.15, 13.1 ], "ebit_estimate": [ -27.54, -28.76, -27.68, -27.34, -27.85, -30.38, -21.75 ], "ebitda_estimate": [ -27.02, -27.98, -30.28, null, null, null, null ], "net_income_estimate": [ -27.01, -28.52, -27.49, -26.73, -27.34, -30, -21.47 ], "per_share_eps_estimate": [ -0.27, -0.27, -0.23, -0.27, -0.27, -0.3, -0.21 ], "eps_nri_estimate": [ -0.27, -0.27, -0.23, -0.27, -0.27, -0.3, -0.21 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ -0.62, -0.91, -1.21, null, null, null, null ], "pretax_income_estimate": [ -27.18, -28.76, -26.98, -26.89, -27.81, -30.74, -17.95 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, -203.46, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 16.11, "long_term_revenue_growth_rate_mean": "-40.60", "future_per_share_eps_estimate_growth": 15.28, "future_eps_nri_estimate_growth": 16.11, "future_revenue_estimate_growth": -40.6, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 25.37, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }